Treatment-resistant anxiety disorders
The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Abstract
Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Several factors are associated with treatment-resistant anxiety, including comorbid physical and mental health conditions, noncompliance and environmental stressors.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Physical and mental health comorbidity (e.g.depression, other anxiety disorders, personality disorders, mild cognitive deficits, physical ill-health, pain) is common in TR-GAD and is associated with poor treatment response.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Although treatment for anxiety disorders produces moderate QOL improvements, not all individuals respond to these front-line interventions, and those who are treatment refractory exhibit particularly low QOL and increased rates of suicide [85].”
From Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research (2021) · cites this paper as [85]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818
Neuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Groves, D. A., & Brown, V. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.01.004 · Cited by 675
Research works printed but not linked: 5
- Nemeroff CB . Remission: today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002; 36: 5.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D . Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long term studies. J Clin Psychopharmacol 2003; 23: 250–259.
- Barlow DH, Gorman JM, Shear MK, Woods SW . Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529–2536. · DOI · Paper page
- Beale MD, Kellner CH, Pritchett JT, Burns CM . ECT for OCD. J Clin Psychiatry 1995; 56: 81–82.
- Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–354. · DOI · Paper page
Cited by
Items 201–289 of 289
Can proteomics‐based diagnostics aid clinical psychiatry?
Filiou, M. D. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400144 · Cited by 3
“Not all patients respond to the same treatment, remission rates are low and a considerable percentage of patients are treatment resistant [23, 24].”
Gallo, A. T., Addis, S., Martyn, V., Ramanathan, H., Wilkerson, G. K., Bennett, K., Hood, S. D., Stampfer, H. G., & Hulse, G. K. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231156400 · Cited by 4
White, S. W., Callahan, H., Smith, S. J., & Padilla, F. M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173880 · Cited by 3
A Psychodynamic Approach to Treatment Resistance
Weinberg, E., Seery, E., & Plakun, E. M. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_20 · Cited by 4
Comparison of cognitive and emotional schema in women with and without marital satisfaction
Najafabadi, Z. P., Alibeigi, N., & Eskandarnia, E. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.12.1.0455 · Cited by 3
Angsterkrankungen und Therapieresistenz: Klinische Empfehlungen und Perspektiven
Zwanzger, P., & Diemer, J. (2019) · Nervenheilkunde · doi:10.1055/a-0961-2589 · Cited by 2
“Dennoch sprechen nach wie vor bis zu einem Drittel der Patienten nicht oder nicht ausreichend auf die Therapie an [6, 7].”
BackgroundPharmacotherapy and cognitive bias modification for the treatment of anxiety disorders
Kong, Q., & Han, B. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2334847 · Cited by 2
“In the field of anxiety disorder treatment, although significant advances have been made in several aspects, many patients fail to respond adequately to existing treatments [80].”
BackgroundMorel, C., Montgomery, S. E., & Han, M. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.03.971 · Cited by 2
Domschke, K., Kapfhammer, H., & Deckert, J. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_69-1 · Cited by 3
Augmentation of Psychotherapy with D-Cycloserine in Patients with Anxiety Disorders
Lautenbacher, L. M., Pyrkosch, L., Mascarell-Maricic, L., & Ströhle, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_446 · Cited by 2
Silva, F. J. D. C., Masella, G., Madeira, M. F., Duarte, C. B., & Santos, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03292-0 · Cited by 3
Interleukin-1 beta in psychosocial stress
Yin, W., Godbout, J. P., & Sheridan, J. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817558-3.00007-x · Cited by 9
Shadli, S. M., Donegan, C. J., Fahmi, M. S. B. M., Russell, B. R., Glue, P., & McNaughton, N. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241275627 · Cited by 2
“Worse, around one-third of anxious or depressed individuals are treatment resistant (TR; Bystritsky, 2006; Souery et al., 2006) – generally defined as a lack of improvement with conventional treatments, usually, after at least two drugs and psychotherapy have been tested (Bokma et al., 2019;…”
BackgroundPereira, C. F., Boileau, I., & Kloiber, S. M. (2025) · Discover Mental Health · doi:10.1007/s44192-025-00155-z · Cited by 4
Rengasamy, M. L., Woody, M. L., Kovats, T., Siegle, G. J., & Price, R. B. (2021) · Cognitive Therapy and Research · doi:10.1007/s10608-021-10205-9 · Cited by 2
“However, many treatments for internalizing disorders are costly, timeintensive, difficult to administer, not effective for all patients, or not easily accessible (Bystritsky 2006).”
BackgroundTibrewal, P., Kanigere, M. K., Looi, J. C., Allison, S. C., & Bastiampillai, T. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221087163 · Cited by 2
“Email: prashanttibrewal@gmail.com DOI: 10.1177/00048674221087163 Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006).”
BackgroundInfluentialVohs, C. J. (2008) · ScholarsArchive at Johnson & Wales University (Johnson & Wales University) · Cited by 3
Wanmaker, S. (2011) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 2
Matos, J. H. B., Silva, A. H. B. D. L., Ferreira, M. V., Verri, W. A., Jr., da Cunha, J. M., & Zanoveli, J. M. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149612 · Cited by 1
O'Sullivan, D. T., Rice, J. M., Lyons, M., & Herring, M. P. (2025) · Psychology of sport and exercise · doi:10.1016/j.psychsport.2025.102902 · Cited by 2
Hur, K., Pizzagalli, D. A., Stover, J., Cayetano, K. R., & Kohut, S. J. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04111-5 · Cited by 1
“While the available pharmacological and psychotherapeutic interventions targeting these pathophysiological mechanisms provide symptomatic relief for some individuals, a substantial proportion of patients continue to experience treatment resistance or incomplete symptom remission [5].”
Norris, L. A., Stanojević, M., Skriner, L. C., Chu, B. C., Aalberg, M., Silverman, W. K., Bodden, D. H. M., Piacentini, J. C., Obradovic, Z., & Kendall, P. C. (2025) · Child Psychiatry & Human Development · doi:10.1007/s10578-025-01873-9 · Cited by 1
“Youth may also experience a decrease in self-efficacy as a result of treatment non-response, and consequently, show a decreased willingness to engage in future, potentially more beneficial treat - ments [22].”
Towards a better understanding of persistence of anxiety disorders: a network perspective
Hoogerwerf, E., Riese, H., Spinhoven, P., Lamers, F., & Goekoop, R. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.101001 · Cited by 1
Kerr, T., Purves, K. L., McGregor, T., Craske, M. G., Barry, T., Lester, K. J., Constantinou, E., Sun, M. M. C., Robinson, O. J., & Eley, T. C. (2026) · Computational Psychiatry · doi:10.5334/cpsy.138 · Cited by 1
Combined Treatment for Anxiety Disorders
Dowd, S. M., & Clark, L. M. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000432862.14260.f1 · Cited by 1
Treatment Resistance in Anxiety Disorder: Generalized Anxiety Disorder and Social Anxiety Disorder
Lee, K. S., & Lee, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_14 · Cited by 1
Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment
Kloiber, S. M., & Konstantinou, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_59 · Cited by 3
Jiang, C., Chen, W., Tao, L., Wang, J., Cheng, K., Zhang, Y., Qi, Z., & Zheng, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1090290 · Cited by 2
“Yet, despite its efficacy, exposure therapy has some shortcomings including high drop-out rate [estimated to be 36% among individuals with PTSD (3)] and relapse rate [the estimated return of fear ranges from 19% to 62% (4)], and it is not always effective (5, 6).”
BackgroundSikki, M., Konikkou, K., Konstantinou, N., & Fanti, K. A. (2025) · Experimental Brain Research · doi:10.1007/s00221-025-07040-9 · Cited by 1
“Pharmacotherapy and cognitive behavior therapy are among the most empirically supported forms of treatment for anxi - ety disorders; however, many patients do not achieve remis - sion status (Bystritsky 2006 ; Springer et al. 2018 ; Strawn et al. 2018 ).”
Second-generation antipsychotic drugs for anxiety disorders
Depping, A. M., Komossa, K., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008120 · Cited by 2
Mullally, M. (2011) · uO Research (University of Ottawa) · doi:10.20381/ruor-3767 · Cited by 4
Sustained Modulation of Deep Brain Circuits with Focused Ultrasonic WavesPreprint
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4310447 · Cited by 1
Marković, V., Rizzo, G., Yavari, F., Vicario, C. M., & Nitsche, M. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646182 · Cited by 1
Filiou, M. D. (2010) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.12539
Vohs, C. J., Gable, R. K., Ward, C. V., Barresi, J., Martel, R., & Slocumb, D. (2008) · OpenCommons - UConn (University of Connecticut)
Pharmacologic Approaches to Medication-Resistant Anxiety in Children and Adolescents
Larson, J. J., dosReis, S., Matthys, M., & Riddle, M. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7784-7_24 · Cited by 1
Ansiedade e depressão de jovens em medida socioeducativa de internação no Distrito Federal
da Silva, M. C. (2011) · Americanae (AECID Library) · Cited by 2
Birrell, L. (2013) · Massey Research Online (Massey University) · Cited by 2
Walsh, R. M. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Campbell‐Sills, L., Roy‐Byrne, P., Craske, M. G., Bystritsky, A., Sullivan, G., & Stein, M. B. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15204
Self-citationde Menezes, G. B., Fontenelle, L. F., Mululo, S. C. C., & Versiani, M. (2007)
Emerging Areas of Transcranial Magnetic Stimulation use in Psychiatry
Kosman, K. A., Lonergan, B. B., Awasthi, S., Hinchman, C. A., & Stern, A. P. (2017) · Future Neurology · doi:10.2217/fnl-2017-0004
Transtorno de ansiedade: investigação da adesão à terapêutica medicamentosa
da Cruz, L. P. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.22.2014.tde-03022015-162019
Innovative pharmakologische Strategien gegen Angststörungen
Kiebs, M., & Hurlemann, R. (2018) · NeuroTransmitter · doi:10.1007/s15016-018-6296-x
Müller, J. D. L. (2016) · Cited by 1
Invaded by Threat: Anxiety and Obsessive-Compulsive Thoughts
Ward, T. J., & Plagnol, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-25823-8_8
Boîte à outil translationnelle du psychiatre face aux situations de résistances et complexes
Amad, A. (2018) · French Journal of Psychiatry · doi:10.1016/s2590-2415(19)30018-2
Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls
Garakani, A., Freire, R. C. R., & Murrough, J. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.662963 · Cited by 4
“While there is support for certain forms of psychotherapy to treat anxiety disorders, there remains concern about lower efficacy of psychotherapies compared to medications (1), and incomplete treatment response, and evidence that patients with certain anxiety disorders, especially GAD and SAD, have high rates of recur…”
BackgroundRemus: System for Remote Deep Brain InterventionsPreprint
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.05.442844
Augmentation of Psychotherapy with D-Cycloserine in Patients with Anxiety Disorders
Lautenbacher, L. M., Pyrkosch, L., Mascarell-Maricic, L., & Ströhle, A. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_446-1
Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment
Kloiber, S. M., & Konstantinou, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_59-1
Remote targeted electrical stimulationPreprint
Cheeniyil, R., & Kubanek, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.09.463785
“Approximately one in three patients across neurological and psychiatric conditions does not respond to drugs or has intolerable side effects (Bystritsky, 2006; Al-Harbi, 2012; Jaffe et al., 2019; Lyons and Pahwa, 2004; Zesiewicz et al., 2010; Elias et al., 2013; Elias et al., 2016; Ferguson, 2001;…”
BackgroundШмакова, І. П., PANINA, S., & Mykhaylenko, V. L. (2021) · Balneo and PRM Research Journal · doi:10.12680/balneo.2021.462
“Due to the limited effectiveness of existing (psychological and pharmacological) treatments, there is a need to develop new methods of treatment based on a deeper understanding of the molecular mechanisms underlying the pathogenesis of anxiety [28, 29, 30].”
MethodCase Formulation for Complexity and Comorbidity in Anxiety Disorders and Depression
Ștefan, S., & David, D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108355605.027
Todd, G., & Branch, R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108355605.026
Abraham, S. (2021) · International Journal of Depression and Anxiety · doi:10.23937/2643-4059/1710025 · Cited by 3
Bibliography: for Psychopharmacology: Treatment-Resistant Disorders
(2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.4.foc550
Gallo, A. T., Addis, S., Martyn, V., Ramanathan, H., Wilkerson, G. K., Hood, S. D., Stampfer, H. G., & Hulse, G. K. (2022) · Behavioral Sciences · doi:10.3390/bs12110430
“This would be particularly beneficial for patients discontinuing first-line treatments due to side effects or those demonstrating treatment resistance, which is estimated to be approximately 30% of patients with anxiety disorders [10].”
BackgroundCombined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_95-1
Childhood trauma: Unfolding the lifelong impact on mental health
Kuzminskaite, E. (2023) · doi:10.5463/thesis.371 · Cited by 4
Time-Selected Simulated Feed Stress: A Novel Rodent Model For Anxiety DisorderPreprint
Zhang, H., Wei, S., Gao, D., Hu, M., Zhao, F., Mou, X., Li, Z., Wangqing, Z., Wang, J., Fengjun, M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4687148
Swanson, L. N., Jones, L. S., Aycart, J. M., Zhu, Z., Rabin, D. M., & Kuhn, T. P. (2024) · medRxiv · doi:10.1101/2024.01.30.24301798
Anxiety: Its Management, Treatment, and Alternative Complementary Medicine
Uppalwar, S. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822265289240306175345
Sasikala, G., Praveena, R., & Meeradevi, A. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00183
Barg, G., Lukacs, J. N., & Algorta, G. P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.012 · Cited by 1
Neuroendocrine Regulation of Anxiety
Onisiforou, A., Zanos, P., & Georgiou, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-56798-8_3
Li, Y., Cho, H., de Rutte, J. L., & Dennis‐Tiwary, T. A. (2024) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-024-10143-2
“…respond to cur - rent psychological and pharmaceutical treatment options, including cognitive behavioral therapy (CBT; Bystritsky, 2006 ; Costello et al., 2003 ), suggesting significant gaps in our understanding of etiology and treatment mechanisms (Bandelow et al., 2013 ; Bystritsky, 2006 ).”
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_95
Evaluation of Different Connectivity Methods for Obsessive Compulsive Disorder Diagnosis
Rashidi, S., Abdipourasl, A., Jamaloo, F., & Rostami, R. (2024) · 2024 32nd International Conference on Electrical Engineering (ICEE) · doi:10.1109/icee63041.2024.10667759
“The predominant pharmacological intervention for OCD includes the administration of clomipramine or selective serotonin reuptake inhibitors (SSRIs), both of which have been shown to produce a therapeutic effect in approximately 50% of individuals, which can become less effective over time [3].”
BackgroundMatsumoto, H., Uchino, T., Funatogawa, T., Mizuno, M., & Nemoto, T. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70039
Use of analgesics and psychotropic medication: Findings from the Lolland- Falster Health StudyPreprint
Bruun-Rasmussen, N. E., Lophaven, S., Rasmussen, M. R., & Lynge, E. (2024) · Research Square · doi:10.21203/rs.3.rs-5694365/v1
Difficult-to-Treat Anxiety: A Neurocomputational Framework
Paulus, M. P., & Stein, M. B. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.03.008 · Cited by 1
Hovmand, O. R., Reinholt, N., Christensen, A. B., Bjørnholm, K., Dilling-Hansen, D., & Arnfred, S. (2025) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2025.2507737
“As a result, many patients with emotional disorders are considered treatment-resistant [9,10].”
Rosário, B. D. A., de Lima, M. P., Vieira, M. G., Leite, L. G., de Aquino, P. É. A., Viana, G. S. D. B., Silveira, E. R., de Brito, D. H. A., Zampieri, D., Ricardo, N. M. P. S., et al. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149791
Schiele, M. A., & Domschke, K. (2025) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-025-4397-1
“In klinischen Studien lassen sich Ansprechraten von circa 30–50 % für die KVT [22, 23] und von rund 60 % für die psychopharmakologische Behandlung [24] von Angststörungen finden.”
Schiele, M. A., & Domschke, K. (2025) · CME · doi:10.1007/s11298-025-4407-0
“In klinischen Studien lassen sich Ansprechraten von circa 30–50 % für die KVT [ 22, 23 ] und von rund 60 % für die psychopharmakologische Behandlung [ 24 ] von Angststörungen finden.”
Effects of Kamikihito on the Noradrenergic System and Its Pharmacokinetic Profile
Oizumi, H., Takiyama, M., Matsumoto, T., Nishiyama, M., & Mizuno, K. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00278
Gould, R. L., Callaghan, T., White, D., Wetherell, J. L., Bursnall, M., Bradburn, M., Wailoo, A., Serfaty, M. A., Graham, C. D., Howard, R. J., et al. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07094-6
“However, it has been estimated that up to 40% of people experience anxiety disorders, including GAD, that do not respond to such first-line treatments [6].”
McNaughton, N., Shadli, S. M., Beaglehole, B., & Glue, P. (2026) · Journal of the Royal Society of New Zealand · doi:10.1002/snz2.70002 · Cited by 1
“About 30% of anxiety (Bystritsky 2006) and depression (Souery et al. 2006) patients are treatment resistant (TR), that is, they do not respond adequately to normally adequate treatment with at least two drugs and one psychological therapy (Bokma et al. 2019).”
Pourquoi aimons-nous tant le parfum de la rose ?
Adrar, I. (2023) · theses.fr (ABES) · doi:10.70675/40a94106z14b5z4bbdza30fz4485bdc8fc10
The heritability of reinforcement learning parameters and their association with anxietyPreprint
Kerr, T., Purves, K. L., McGregor, T., Barry, T. J., Lester, K. J., Robinson, O. J., & Eley, T. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727613
Bermudes, R. A., Lanocha, K. I., & Janicak, P. G. (2024) · Transcranial magnetic stimulation . · doi:10.1176/appi.books.9798894550671.fm03
Roberts, L., Cumming, C., Budgeon, C. A., Preen, D. B., & Lee, K. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02176-2
“Anxiety management commonly involves psychotropic medications, such as benzodiazepines or antidepressants, and cognitive behavioural therapies [18].”
Angst- oder furchtbezogene Störungen
Domschke, K., & Zwanzger, P. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_69-2
Rice, J. M., O'Sullivan, D. T., Gordon, B. R., Lindheimer, J. B., Monroe, D. C., Lyons, M., & Herring, M. P. (2026) · Mental health and physical activity · doi:10.1016/j.mhpa.2026.100796
Luo, P., Wu, W., Peng, H., He, D., Guo, Y., Zhao, B., Wang, X. N., Ma, L., Qin, Y., Zhai, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.76479
“However, a substantial percentage of patients, ranging from 20% to 30%, does not respond to these treatments [ 5 ], and many experience severe adverse effects such as jitteriness, nausea, fatigue, and headache [ 6, 7 ].”
Next-Generation Neuromodulation for Anxiety: Circuit-Based and Personalized Approaches
O’Rourke, C. M., Selheimer, R. L., Halpern, C. H., & Oathes, D. J. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01702-3
Hallab, A., The Health and Aging Brain Study (HABS-HD) Study Team*, O’Bryant, S. E., Yaffe, K. S., Toga, A. W., Rissman, R. A., Johnson, L. A., Braskie, M. N., King, K., Hall, J. R., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-69096-z · Cited by 5
“The same proportion of patients with anxiety disorders is considered “treatment-resistant” despite the well-known efficacity of SSRIs and psychotherapy in this condition 94 .”
Metadata
- Authors
- Bystritsky, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bystritsky, A
- ORCID
- Bystritsky, A
- Venue
- Molecular Psychiatry
- Published
- 2006-07-18
- Volume
- 11
- Issue
- 9
- Pages
- 805-814
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2004241099
- Cited by
- 289
- References
- 88
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 10 · 2019: 22 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 10 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxiety disorders, treatment resistance, serotonin reuptake inhibitors, cognitive behavioral therapy, residual symptoms, suicide attempts, quality of life, chronic anxiety, biological factors, social factors
- MeSH terms
- Anxiety Disorders, Humans, United States, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.